Drugs / BX004-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05010577 | Jun 2022 → Mar 2024 | Pseudomonas aeruginosa infectious disease, cystic fibrosis | BiomX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BX004-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05010577 ↗ |
| Modality | Other / unclassified | “Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa” NCT05010577 ↗ |
| Route | Inhaled | “standard dose of nebulized bacteriophage” NCT05010577 ↗ |